// App-Quantinova.ai

FRI0445 : Tildrakizumab Treatment Improved Measures of Psoriatic Arthritis in Adults with Chronic Plaque Psoriasis

Researchers

Presenter

  • R.G. Langley

Principal Investigators

  • D. Thaci

  • K. Reich

  • K. Papp

  • A. Mehta

  • Q. Li

  • C. La Rosa

Medical Centers

  • Probity Clinical Research, Waterloo, ON, Canada

  • SCIderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany

Locations

  • Canada

  • Germany

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriatic arthritis

  • Psoriasis

  • Inflammatory Arthritis

Biomarkers

  • Nucleoside diphosphate kinase A

  • C reactive protein

  • High sensitivity C-reactive protein

Drug/Treatment

  • Tildrakizumab

  • MK-3222

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved